Capsule Summaries

Share

Program Content

Activities

EMBER 3
EMBER-3: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After Progression on Prior ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: June 12, 2025

KEYNOTE 522 Subgroup Analyses
KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: June 15, 2025

SOLTI VALENTINE
Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

PADMA
PADMA: ET + Palbociclib vs Standard Chemotherapy in High-Risk HR+/HER2- MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

ELECTRA and ELEVATE
ELECTRA and ELEVATE: Elacestrant Combinations for ER+/HER2- Advanced/Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

Provided by

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation